Magellan Life Sciences
Discovering, deciphering, and developing unique plant proteins
- Employees
- 1–10
- Founded
- 2013
- Business Model
- B2B
- Website
- magellanlifesciences.com
- Total Funding
- $1.2M
About
Magellan Life Sciences is a synthetic biology company that uses its proprietary X-Seed® Precision Respiration™ platform to engineer and commercialize complex plant proteins at industrial scale. Their lead program focuses on Brazzein, a rare natural protein sweetener derived from West African fruit, as a sustainable alternative to sugar and high-fructose corn syrup. The company's platform offers higher yields and simplified downstream purification compared to conventional bioprocessing, targeting the food security and alternative sweetener markets. MLS was part of SOSV's IndieBio 2018 cohort, received Innovate UK grants, and received interest from Roquette Ventures.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account